Core Points - Vaxil Bio Ltd. announced a non-brokered private placement offering of up to 3,111,111 units at a price of $0.1125 per unit, aiming to raise gross proceeds of up to $350,000 [2][3] - Each unit consists of one common share and one share purchase warrant, with warrants allowing the purchase of additional shares at $0.15 for five years [2] - The net proceeds will be used for general corporate purposes, and the offering is expected to close around December 4, 2025, pending approval from the TSX Venture Exchange [3] Financial Details - The company will pay finders a cash commission of up to 8% of the gross proceeds and issue non-transferrable warrants equal to 8% of the total units issued [4] - The units, shares, and warrants will be subject to a hold period of four months and one day from the date of issue [4] Company Background - Vaxil is an immunotherapy biotech company focused on targeting cancer markers and infectious diseases, with its lead product being ImMucin™, which has received orphan drug status from the FDA and EMA [5] - The company is exploring other business opportunities to enhance shareholder value, which may or may not be within the biotechnology sector [5]

Core Viewpoint - Vaxil Bio Ltd. is planning a non-brokered private placement to raise up to $350,000 through the issuance of units priced at $0.1425 each, which will include common shares and warrants [1][2]. Group 1: Offering Details - The offering will consist of up to 2,456,140 units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant will allow the holder to purchase one share at a price of $0.19 for five years post-closing [1]. - The expected closing date for the offering is around November 14, 2025, pending approval from the TSX Venture Exchange [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to support general corporate purposes [2]. Group 3: Finder's Fees - The company will pay finders a cash commission of up to 8% of the gross proceeds and non-transferrable warrants equal to up to 8% of the total units issued [3]. - The units, shares, and warrants will be subject to a hold period of four months and one day from the issuance date [3]. Group 4: Company Background - Vaxil is an immunotherapy biotech company focused on targeting cancer markers and infectious diseases, with its lead product being ImMucin™, which has received orphan drug status from the FDA and EMA [4]. - The company is exploring other business opportunities that may or may not be within the biotechnology sector to enhance shareholder value [4].

Core Points - Vaxil Bio Ltd. will consolidate its common shares at a ratio of one post-consolidation share for every fifty pre-consolidation shares [1][2] - The effective date for the consolidation is set for May 15, 2025, with trading on a post-consolidation basis expected to commence on or about the same date [2] - The total number of outstanding common shares will decrease from approximately 136,978,973 to about 2,739,579 post-consolidation [3] Shareholder Information - Registered shareholders will receive letters of transmittal and must deposit their share certificates with Computershare Investor Services Inc. [4] - Non-registered shareholders should check with their intermediaries for specific procedures regarding the consolidation [4] Financial Instruments Adjustment - Outstanding stock options and share purchase warrants will be adjusted according to the consolidation ratio, affecting their respective exercise prices [5] Company Overview - Vaxil is an Israeli biotech company focused on immunotherapy, particularly its lead product ImMucin™, which has completed a Phase 1/2 clinical trial for multiple myeloma and received orphan drug status from the FDA and EMA [6] - The company is currently evaluating whether to continue developing ImMucin™ or explore other business opportunities to enhance shareholder value [6]